TISIDB

Summary
Symbol	SPTBN5
Name	spectrin, beta, non-erythrocytic 5
Aliases	HUSPECV; BSPECV; HUBSPECV; beta V spectrin; beta-V spectrin; spectrin beta chain, brain 4; spectrin, non-ery ......
Chromosomal Location	15q21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Cytoplasm, cytoskeleton. Note=Detected prominently in the outer segments of photoreceptor rods and cones and in the basolateral membrane and cytosol of gastric epithelial cells.
Domain	PF00307 Calponin homology (CH) domain PF00435 Spectrin repeat
Function	-

> Gene Ontology [ TOP ]
Biological Process	GO:0006888 ER to Golgi vesicle-mediated transport GO:0007015 actin filament organization GO:0007030 Golgi organization GO:0007034 vacuolar transport GO:0007041 lysosomal transport GO:0007409 axonogenesis GO:0007411 axon guidance GO:0008064 regulation of actin polymerization or depolymerization GO:0008154 actin polymerization or depolymerization GO:0010639 negative regulation of organelle organization GO:0030041 actin filament polymerization GO:0030042 actin filament depolymerization GO:0030832 regulation of actin filament length GO:0030833 regulation of actin filament polymerization GO:0030834 regulation of actin filament depolymerization GO:0030835 negative regulation of actin filament depolymerization GO:0030837 negative regulation of actin filament polymerization GO:0031333 negative regulation of protein complex assembly GO:0032271 regulation of protein polymerization GO:0032272 negative regulation of protein polymerization GO:0032535 regulation of cellular component size GO:0032956 regulation of actin cytoskeleton organization GO:0032970 regulation of actin filament-based process GO:0032984 macromolecular complex disassembly GO:0043241 protein complex disassembly GO:0043242 negative regulation of protein complex disassembly GO:0043244 regulation of protein complex disassembly GO:0043254 regulation of protein complex assembly GO:0043624 cellular protein complex disassembly GO:0048193 Golgi vesicle transport GO:0048667 cell morphogenesis involved in neuron differentiation GO:0051258 protein polymerization GO:0051259 protein oligomerization GO:0051260 protein homooligomerization GO:0051261 protein depolymerization GO:0051493 regulation of cytoskeleton organization GO:0051494 negative regulation of cytoskeleton organization GO:0051693 actin filament capping GO:0061564 axon development GO:0090066 regulation of anatomical structure size GO:0097485 neuron projection guidance GO:1901879 regulation of protein depolymerization GO:1901880 negative regulation of protein depolymerization
Molecular Function	GO:0003779 actin binding GO:0005085 guanyl-nucleotide exchange factor activity GO:0005088 Ras guanyl-nucleotide exchange factor activity GO:0017022 myosin binding GO:0019894 kinesin binding GO:0030507 spectrin binding GO:0032029 myosin tail binding GO:0032036 myosin heavy chain binding GO:0034452 dynactin binding GO:0043621 protein self-association GO:0045502 dynein binding GO:0045505 dynein intermediate chain binding
Cellular Component	GO:0001750 photoreceptor outer segment GO:0005929 cilium GO:0005938 cell cortex GO:0008091 spectrin GO:0015629 actin cytoskeleton GO:0030863 cortical cytoskeleton GO:0030864 cortical actin cytoskeleton GO:0031253 cell projection membrane GO:0031513 nonmotile primary cilium GO:0032391 photoreceptor connecting cilium GO:0044441 ciliary part GO:0044448 cell cortex part GO:0060170 ciliary membrane GO:0072372 primary cilium GO:0097381 photoreceptor disc membrane GO:0099568 cytoplasmic region

> KEGG and Reactome Pathway [ TOP ]
KEGG	-
Reactome	R-HSA-170984: ARMS-mediated activation R-HSA-446203: Asparagine N-linked glycosylation R-HSA-422475: Axon guidance R-HSA-6807878: COPI-mediated anterograde transport R-HSA-1280215: Cytokine Signaling in Immune system R-HSA-2172127: DAP12 interactions R-HSA-2424491: DAP12 signaling R-HSA-1266738: Developmental Biology R-HSA-186763: Downstream signal transduction R-HSA-199977: ER to Golgi Anterograde Transport R-HSA-2871796: FCERI mediated MAPK activation R-HSA-2454202: Fc epsilon receptor (FCERI) signaling R-HSA-170968: Frs2-mediated activation R-HSA-179812: GRB2 events in EGFR signaling R-HSA-881907: Gastrin-CREB signalling pathway via PKC and MAPK R-HSA-2428924: IGF1R signaling cascade R-HSA-112399: IRS-mediated signalling R-HSA-2428928: IRS-related events triggered by IGF1R R-HSA-168256: Immune System R-HSA-168249: Innate Immune System R-HSA-74751: Insulin receptor signalling cascade R-HSA-445095: Interaction between L1 and Ankyrins R-HSA-912526: Interleukin receptor SHC signaling R-HSA-451927: Interleukin-2 signaling R-HSA-512988: Interleukin-3, 5 and GM-CSF signaling R-HSA-373760: L1CAM interactions R-HSA-5683057: MAPK family signaling cascades R-HSA-5684996: MAPK1/MAPK3 signaling R-HSA-199991: Membrane Trafficking R-HSA-392499: Metabolism of proteins R-HSA-375165: NCAM signaling for neurite out-growth R-HSA-187037: NGF signalling via TRKA from the plasma membrane R-HSA-597592: Post-translational protein modification R-HSA-169893: Prolonged ERK activation events R-HSA-5673001: RAF/MAP kinase cascade R-HSA-8853659: RET signaling R-HSA-180336: SHC1 events in EGFR signaling R-HSA-112412: SOS-mediated signalling R-HSA-162582: Signal Transduction R-HSA-177929: Signaling by EGFR R-HSA-372790: Signaling by GPCR R-HSA-74752: Signaling by Insulin receptor R-HSA-449147: Signaling by Interleukins R-HSA-2586552: Signaling by Leptin R-HSA-186797: Signaling by PDGF R-HSA-1433557: Signaling by SCF-KIT R-HSA-2404192: Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R) R-HSA-194138: Signaling by VEGF R-HSA-166520: Signalling by NGF R-HSA-187687: Signalling to ERKs R-HSA-167044: Signalling to RAS R-HSA-187706: Signalling to p38 via RIT and RIN R-HSA-948021: Transport to the Golgi and subsequent modification R-HSA-4420097: VEGFA-VEGFR2 Pathway R-HSA-5218921: VEGFR2 mediated cell proliferation R-HSA-5653656: Vesicle-mediated transport

> KEGG and Reactome Pathway

[ TOP ]

KEGG

Reactome

R-HSA-170984: ARMS-mediated activation
R-HSA-446203: Asparagine N-linked glycosylation
R-HSA-422475: Axon guidance
R-HSA-6807878: COPI-mediated anterograde transport
R-HSA-1280215: Cytokine Signaling in Immune system
R-HSA-2172127: DAP12 interactions
R-HSA-2424491: DAP12 signaling
R-HSA-1266738: Developmental Biology
R-HSA-186763: Downstream signal transduction
R-HSA-199977: ER to Golgi Anterograde Transport
R-HSA-2871796: FCERI mediated MAPK activation
R-HSA-2454202: Fc epsilon receptor (FCERI) signaling
R-HSA-170968: Frs2-mediated activation
R-HSA-179812: GRB2 events in EGFR signaling
R-HSA-881907: Gastrin-CREB signalling pathway via PKC and MAPK
R-HSA-2428924: IGF1R signaling cascade
R-HSA-112399: IRS-mediated signalling
R-HSA-2428928: IRS-related events triggered by IGF1R
R-HSA-168256: Immune System
R-HSA-168249: Innate Immune System
R-HSA-74751: Insulin receptor signalling cascade
R-HSA-445095: Interaction between L1 and Ankyrins
R-HSA-912526: Interleukin receptor SHC signaling
R-HSA-451927: Interleukin-2 signaling
R-HSA-512988: Interleukin-3, 5 and GM-CSF signaling
R-HSA-373760: L1CAM interactions
R-HSA-5683057: MAPK family signaling cascades
R-HSA-5684996: MAPK1/MAPK3 signaling
R-HSA-199991: Membrane Trafficking
R-HSA-392499: Metabolism of proteins
R-HSA-375165: NCAM signaling for neurite out-growth
R-HSA-187037: NGF signalling via TRKA from the plasma membrane
R-HSA-597592: Post-translational protein modification
R-HSA-169893: Prolonged ERK activation events
R-HSA-5673001: RAF/MAP kinase cascade
R-HSA-8853659: RET signaling
R-HSA-180336: SHC1 events in EGFR signaling
R-HSA-112412: SOS-mediated signalling
R-HSA-162582: Signal Transduction
R-HSA-177929: Signaling by EGFR
R-HSA-372790: Signaling by GPCR
R-HSA-74752: Signaling by Insulin receptor
R-HSA-449147: Signaling by Interleukins
R-HSA-2586552: Signaling by Leptin
R-HSA-186797: Signaling by PDGF
R-HSA-1433557: Signaling by SCF-KIT
R-HSA-2404192: Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)
R-HSA-194138: Signaling by VEGF
R-HSA-166520: Signalling by NGF
R-HSA-187687: Signalling to ERKs
R-HSA-167044: Signalling to RAS
R-HSA-187706: Signalling to p38 via RIT and RIN
R-HSA-948021: Transport to the Golgi and subsequent modification
R-HSA-4420097: VEGFA-VEGFR2 Pathway
R-HSA-5218921: VEGFR2 mediated cell proliferation
R-HSA-5653656: Vesicle-mediated transport

Summary
Symbol	SPTBN5
Name	spectrin, beta, non-erythrocytic 5
Aliases	HUSPECV; BSPECV; HUBSPECV; beta V spectrin; beta-V spectrin; spectrin beta chain, brain 4; spectrin, non-ery ......
Chromosomal Location	15q21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between SPTBN5 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining [ TOP ]
There is no record.

Summary
Symbol	SPTBN5
Name	spectrin, beta, non-erythrocytic 5
Aliases	HUSPECV; BSPECV; HUBSPECV; beta V spectrin; beta-V spectrin; spectrin beta chain, brain 4; spectrin, non-ery ......
Chromosomal Location	15q21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of SPTBN5 in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	SPTBN5
Name	spectrin, beta, non-erythrocytic 5
Aliases	HUSPECV; BSPECV; HUBSPECV; beta V spectrin; beta-V spectrin; spectrin beta chain, brain 4; spectrin, non-ery ......
Chromosomal Location	15q21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of SPTBN5 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	-0.081	0.626
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	-0.044	0.913
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	-0.107	0.75
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	-0.558	0.176
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	-0.888	0.688
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	-0.142	0.959
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	1.308	0.00353
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	1.817	0.00988
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	0.782	0.305
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	-0.021	0.953
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	0.05	0.928
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	-0.234	0.142

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of SPTBN5 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	35.7	0	35.7	0.0118
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	30	0	30	0.528
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	50	0	50	0.0392
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	14.8	2.7	12.1	0.0439
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	14.8	3.4	11.4	0.0746
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	4.8	5.9	-1.1	1
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	0	0	0	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	7.7	9.1	-1.4	1
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0	12.5	-12.5	0.52
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	22.2	-22.2	0.505
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	0	0	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	7.9	3.7	4.2	0.636
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	13.6	7.7	5.9	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	0	0	0	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	0	1

Summary
Symbol	SPTBN5
Name	spectrin, beta, non-erythrocytic 5
Aliases	HUSPECV; BSPECV; HUBSPECV; beta V spectrin; beta-V spectrin; spectrin beta chain, brain 4; spectrin, non-ery ......
Chromosomal Location	15q21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of SPTBN5. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	SPTBN5
Name	spectrin, beta, non-erythrocytic 5
Aliases	HUSPECV; BSPECV; HUBSPECV; beta V spectrin; beta-V spectrin; spectrin beta chain, brain 4; spectrin, non-ery ......
Chromosomal Location	15q21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of SPTBN5. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by SPTBN5. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	SPTBN5
Name	spectrin, beta, non-erythrocytic 5
Aliases	HUSPECV; BSPECV; HUBSPECV; beta V spectrin; beta-V spectrin; spectrin beta chain, brain 4; spectrin, non-ery ......
Chromosomal Location	15q21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of SPTBN5. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	SPTBN5
Name	spectrin, beta, non-erythrocytic 5
Aliases	HUSPECV; BSPECV; HUBSPECV; beta V spectrin; beta-V spectrin; spectrin beta chain, brain 4; spectrin, non-ery ......
Chromosomal Location	15q21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of SPTBN5 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	SPTBN5
Name	spectrin, beta, non-erythrocytic 5
Aliases	HUSPECV; BSPECV; HUBSPECV; beta V spectrin; beta-V spectrin; spectrin beta chain, brain 4; spectrin, non-ery ......
Chromosomal Location	15q21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between SPTBN5 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	SPTBN5
Name	spectrin, beta, non-erythrocytic 5
Aliases	HUSPECV; BSPECV; HUBSPECV; beta V spectrin; beta-V spectrin; spectrin beta chain, brain 4; spectrin, non-ery ......
Chromosomal Location	15q21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting SPTBN5 collected from DrugBank database.

> Drugs from DrugBank database [ TOP ]
There is no record.

Browse SPTBN5